Neurology Times Provides Neurologists New Tools for Success
An examination of 10 CEFs with the highest duration risk.
We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.
Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)